If you searched semaglutide before and after, the honest answer is a timeline, not a pair of photographs. In the STEP trials, the first month was an adjustment period, weight continued to change through month six, and the group curve slowed only after about a year. Some people changed earlier or later, and some changed very little. A photo cannot show dose, starting health, side effects, or what happened after treatment stopped. The useful answer is a series of measured checkpoints.
Why photographs are weak evidence
A photograph captures one second. Lighting, posture, clothing, camera distance, meal timing, and deliberate selection can all change what that second appears to show. It also cannot tell whether semaglutide caused the difference.
Clinical trials work differently. They record measurements on a schedule, include everyone assigned to a group in the main analysis, and compare that group with a placebo group, which receives an inactive treatment. That still does not predict one person's path, but it is much harder to shape than a chosen image. This site does not publish before-and-after photos because they turn an individual moment into an implied promise.
Semaglutide before and after, month by month
Semaglutide is a GLP-1 receptor agonist, a medicine that copies one of the body's meal-related signals. The STEP 1 trial followed 1,961 adults without diabetes for 68 weeks. Its published graph shows a steady average decline rather than one dramatic drop (Wilding and colleagues, New England Journal of Medicine, 2021).
| Checkpoint | What the studies show | What it does not mean |
|---|---|---|
| Weeks 1–4 | STEP 1 began at a lower study dose. The average weight curve had started moving, but this was an initiation period. | A quiet first month does not predict the final result. |
| Weeks 5–20 | Dose escalation, the planned gradual increase used in the trial, continued while the group curve kept descending. | The study schedule is not a personal dosing instruction. |
| Around month 6 | Participants were past the build-up period, yet the average curve was still moving. | Six months was not the trial's finish line. |
| Around months 12–15 | The STEP 1 curve became less steep near week 60. | An average curve flattening does not set a deadline for one person. |
| Up to 2 years | STEP 5 found that the average change was largely maintained through week 104 among people assigned to ongoing treatment. | Continued group results do not guarantee an individual outcome. |
The companion guide to semaglutide weight-loss results has the final trial numbers. The useful point here is the shape: early change, a long middle, then a slower phase.
What the first month may feel like
The first noticeable change may be less interest in food or feeling full sooner. Another person may notice nausea, diarrhea, or no clear change at all. In STEP 1, nausea and diarrhea were usually temporary and mild to moderate, but 4.5% of the semaglutide group stopped because of stomach or bowel effects.
That is why the first month is a poor audition for the next year. The amount of medicine circulating was still building, and the body was still adjusting. A daily photo or a single weigh-in adds noise. A trend recorded under similar conditions tells a clinician more.
Month six is a checkpoint, not a verdict
By month six, the STEP curves had separated clearly from placebo, but they had not reached their later flat stretch. The more useful review asks whether appetite, tolerability (how manageable side effects are), waist measurement, blood pressure, blood sugar when relevant, and weight trend are moving together. It does not ask whether someone resembles an online photograph.
As of September 9, 2026, the day this article was written, the newest relevant peer-reviewed result was STEP 12, published online August 10, 2026. In that 44-week trial of 242 Chinese adults, the semaglutide group averaged a 12.1% body-weight reduction and the placebo group 2.2%; both groups also received lifestyle support (The Lancet Diabetes & Endocrinology, 2026). It adds a different population and a shorter timeline, not a forecast for any one reader.
A plateau is part of the curve
A plateau is a period when average weight changes little. In STEP 5, the group curve flattened around week 60 and then stayed broadly stable through two years (Garvey and colleagues, Nature Medicine, 2022). That pattern is easy to misread as the medicine suddenly failing.
For an individual, a flat stretch can reflect many things: normal week-to-week variation, a dose being held for tolerability, changes in eating or movement, another medication, or the body settling at a new balance. The prescriber can interpret the trend in context. A photograph cannot.
Do not borrow a tirzepatide timeline
Tirzepatide activates GLP-1 plus GIP, another meal-related signal. Its trial averages and timing are not interchangeable with semaglutide's. A clinician may consider it as a different prescription option, but another drug's curve is not a target for someone taking semaglutide.
What happens when treatment stops
STEP 4 makes the timeline especially clear. Everyone first received semaglutide for 20 weeks. Then 803 adults were randomly assigned either to continue or switch to placebo while lifestyle support continued. Over the next 48 weeks, the continuation group lost another 7.9% on average, while the switch group regained 6.9% (Rubino and colleagues, JAMA, 2021).
That does not mean everyone regains the same amount. It means the on-treatment and off-treatment curves moved in opposite directions at the group level. The fuller guide to what happens when semaglutide stops covers the follow-up without turning it into a prediction.
Where compounded semaglutide fits
Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A compounded medication is prepared by a licensed pharmacy for an individual prescription rather than sold as the branded trial product. The STEP studies above therefore provide context about the molecule, not trial evidence for Promise's specific formulation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
Bring a trend, not a transformation
A useful follow-up can be simple: dates, weights taken under similar conditions, appetite changes, side effects, and any relevant home readings or lab work the prescriber requested. The point is not to inspect the body for a dramatic reveal. It is to see whether the plan remains appropriate, tolerable, and useful over time.
That record also leaves room for an honest answer when the curve is slower than hoped. Trial averages describe groups. Care happens one measured checkpoint at a time.